Although a controversial decision, the FDA has approved Biogen’s Alzheimer’s drug, Aduhelm – and the decision caused Biogen’s stock to surge more than 60% in one day. On the heels of this, and with novel drug approvals on the rise, the contributors to today’s article discuss Biogen’s approval “and how ‘novel’ drugs can give biotech stocks a leg up … and give substantial profit to investors.” For more, CLICK HERE.